A61K39/02

METHODS FOR PROVIDING CONTINUOUS THERAPY AGAINST PNAG COMPRISING MICROBES
20230053458 · 2023-02-23 ·

Disclosed are antimicrobial vaccines comprising oligosaccharide β-(1.fwdarw.6)-glucosamine groups.

METHODS FOR PROVIDING CONTINUOUS THERAPY AGAINST PNAG COMPRISING MICROBES
20230053458 · 2023-02-23 ·

Disclosed are antimicrobial vaccines comprising oligosaccharide β-(1.fwdarw.6)-glucosamine groups.

TABLETIZATION OF PEPTIDE SELF-ASSEMBLIES AND METHODS OF MAKING AND USING THE SAME
20220362159 · 2022-11-17 ·

The present disclosure provides, in part, peptide self-assemblies that are made into tablet form and methods of making and using the same. In some embodiments, the disclosure provides methods and formulations for a tabletized form of a vaccine, particularly a vaccine comprising self-assembling peptide-polymer nanofibers, an excipient and an adjuvant. Methods of making and using the tablet formulation are also provided.

Toll-like receptor 2 agonists and vaccines and uses thereof

The present invention relates to Toll-Like Receptor 2 (TLR2) agonists, in particular, to TLR2-activating lipoproteins, and more particularly to TLR2-activating lipopeptides derived from the bacteria Bordetella pertussis. The invention further extends to the use of said TLR2-activating lipoproteins as a therapeutic or as part of a vaccine composition in the treatment and prevention of infectious diseases, cancer or allergic diseases.

Live attenuated heterologous vaccine for <i>Leptospira </i>

The present invention provides compositions or vaccines that contain a recombinant or an attenuated Leptospira interrogans that elicit an immune response in animals against Leptospira infection, including compositions comprising said recombinant or attenuated L. interrogans, methods of vaccination against Leptospira, and kits for use with such methods and compositions.

FimH mutant, compositions therewith and use thereof

Polypeptides comprising a FimH lectin domain comprising an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.

Therapeutic Agent Effectiveness and its Route of Adminstration
20220354943 · 2022-11-10 · ·

Disclosed herein are methods for generating a protective immunogenic response via intranasal administration of an immunogenic composition (e.g., vaccine)/therapeutic immunogenic composition in a mammalian subject. Certain dosing positions of the subject during the administration of immunogenic agents, such that nostrils are tilted upwards, while in a modified sitting, reclining and/or supine posture, is surprisingly correlated with the generation of a strong immunogenic response in both humans and animals.

BEE VACCINES AND METHODS OF USE
20220354940 · 2022-11-10 ·

The disclosure provides compositions and methods for treating and vaccinating insects and insect populations from bacterial diseases. The disclosure further provides compositions and methods for prophylactically immunizing honeybee hive to protect from infection with Foulbrood disease. In embodiments, the disclosure further provides compositions and methods for prophylactically immunizing honeybee hive to protect from infection with American foulbrood caused by Paenibaccilus larvae.

Antigenic combinations against <i>Francisella </i>bacteria and related nanolipoprotein particles, compositions, methods and systems

Provided herein are antigenic combinations and related compositions, methods and systems for immunizing a host from an infection caused by Francisella bacterium. The antigenic combination comprises an antigenic polysaccharide component from a Francisella bacterium capable of triggering a humoral immune response in an individual, a protein antigen component from the Francisella bacterium capable of triggering a cellular immune response in the individual, and an adjuvant, the antigenic Francisella polysaccharide component, the Francisella protein antigen component and the adjuvant are in a suitable amount to immunize an individual against the Francisella bacterium.

Antigenic combinations against <i>Francisella </i>bacteria and related nanolipoprotein particles, compositions, methods and systems

Provided herein are antigenic combinations and related compositions, methods and systems for immunizing a host from an infection caused by Francisella bacterium. The antigenic combination comprises an antigenic polysaccharide component from a Francisella bacterium capable of triggering a humoral immune response in an individual, a protein antigen component from the Francisella bacterium capable of triggering a cellular immune response in the individual, and an adjuvant, the antigenic Francisella polysaccharide component, the Francisella protein antigen component and the adjuvant are in a suitable amount to immunize an individual against the Francisella bacterium.